Cyclosporine therapy for advanced Langerhans cell histiocytosis [see
comments]
HH Mahmoud, WC Wang and SB Murphy
Department of Hematology-Oncology, St. Jude Children's Research Hospital,
Memphis, TN 38101.
Prompted by evidence that Langerhans cell histiocytosis (LCH) is a
nonmalignant disorder of immune regulation, we used cyclosporine (12
mg/kg/d orally) to treat three young children with advanced multisystem
LCH. All three patients had partial responses to cyclosporine within 2
months of therapy, as evidenced by complete resolution of organ dysfunction
and regression of the majority of lesions. Complete responses were attained
by adding relatively nontoxic chemotherapy (ie, prednisone and
vinblastine). Toxicity from cyclosporine comprised mild and reversible
elevations of the serum creatinine and blood urea nitrogen. These results
indicate that further evaluation of cyclosporine for the treatment of
patients with advanced LCH is warranted.
Volume 77,
Issue 4,
pp. 721-725,
02/15/1991
Copyright © 1991 by The American Society of Hematology
